Compare BBSI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | SNDX |
|---|---|---|
| Founded | 1965 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.4M | 1.7B |
| IPO Year | 1993 | 2016 |
| Metric | BBSI | SNDX |
|---|---|---|
| Price | $36.80 | $20.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $45.50 | $36.92 |
| AVG Volume (30 Days) | 207.1K | ★ 2.1M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ 10.03 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $1,223,992,000.00 | $111,304,000.00 |
| Revenue This Year | $10.70 | $620.14 |
| Revenue Next Year | $7.58 | $115.42 |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | 9.64 | ★ 595.65 |
| 52 Week Low | $33.01 | $8.58 |
| 52 Week High | $49.65 | $21.22 |
| Indicator | BBSI | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 68.24 |
| Support Level | $33.78 | $20.00 |
| Resistance Level | $37.12 | $21.22 |
| Average True Range (ATR) | 0.90 | 0.90 |
| MACD | 0.47 | 0.02 |
| Stochastic Oscillator | 91.78 | 85.48 |
Barrett Business Services Inc is a provider of payroll administrative services and staffing services. The company categories of services include professional employer services and staffing. Professional employer services offer payroll management, payroll tax services, and workers' compensation coverage solutions, as well as workforce management services, including hiring and termination of employees. Staffing offers temporary staffing services, as well as contract staffing, long-term or indefinite on-site management, and direct placement services. The company operates in the United States of America. It generates maximum revenue from the Professional employer service fees.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.